The estimated Net Worth of Colleen Tupper is at least $6.24 million dollars as of 28 May 2024. Ms Tupper owns over 19,710 units of Collegium Pharmaceutical Inc stock worth over $4,736,589 and over the last 3 years she sold COLL stock worth over $1,501,834.
Ms has made over 3 trades of the Collegium Pharmaceutical Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 19,710 units of COLL stock worth $674,279 on 28 May 2024.
The largest trade she's ever made was selling 31,640 units of Collegium Pharmaceutical Inc stock on 15 March 2023 worth over $752,083. On average, Ms trades about 7,957 units every 86 days since 2021. As of 28 May 2024 she still owns at least 130,845 units of Collegium Pharmaceutical Inc stock.
You can see the complete history of Ms Tupper stock trades at the bottom of the page.
Colleen Tupper is the Exec. VP & CFO at Collegium Pharmaceutical Inc.
Colleen's mailing address filed with the SEC is C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072.
Over the last 10 years, insiders at Collegium Pharmaceutical Inc have traded over $80,399,308 worth of Collegium Pharmaceutical Inc stock and bought 1,112,375 units worth $13,316,951 . The most active insiders traders include Group Holdings (Sbs) Adviso..., John Gordon Freund et David Hirsch. On average, Collegium Pharmaceutical Inc executives and independent directors trade stock every 35 days with the average trade being worth of $2,130,406. The most recent stock trade was executed by Shirley R. Kuhlmann on 5 September 2024, trading 20,225 units of COLL stock currently worth $773,809.
collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex
Collegium Pharmaceutical Inc executives and other stock owners filed with the SEC include: